(self.webpackChunk_N_E=self.webpackChunk_N_E||[]).push([[1203],{38140:function(e,t,i){Promise.resolve().then(i.bind(i,75520))},75520:function(e,t,i){"use strict";i.r(t),i.d(t,{default:function(){return S}});var n=i(57437),a=i(2265),o=i(25553),s=i(49739),r=i(10949),c=i(29268),l=i(18776),h=i(29951),d=i(57972),g=i(96063),u=i(75962),m=i(15530),p=i(37395),f=i(66031),y=i(45531),b=i(32238),v=i(66437),x=i(9778),w=i(52901),j=i(55148),k=i(27648),C=i(24989),P=i(78705),T=i(86449);function S(){let{data:e,loading:t}=(0,o.k)("biotech/biotech_per_year.json"),{data:i,loading:S}=(0,o.k)("biotech/biotech_by_subfield.json"),{data:B,loading:N}=(0,o.k)("biotech/biotech_top_assignees.json"),{data:A,loading:_}=(0,o.k)("biotech/biotech_top_inventors.json"),{data:z,loading:E}=(0,o.k)("biotech/biotech_geography.json"),{data:R,loading:D}=(0,o.k)("biotech/biotech_quality.json"),{data:I,loading:M}=(0,o.k)("biotech/biotech_org_over_time.json"),{data:L}=(0,o.k)("biotech/biotech_strategies.json"),{data:U,loading:q}=(0,o.k)("biotech/biotech_diffusion.json"),{data:H,loading:K}=(0,o.k)("biotech/biotech_team_comparison.json"),{data:G,loading:O}=(0,o.k)("biotech/biotech_assignee_type.json"),{data:Z,loading:F}=(0,o.k)("biotech/biotech_entrant_incumbent.json"),{data:V,loading:J}=(0,o.k)("biotech/biotech_quality_bifurcation.json"),{data:W,loading:Q}=(0,o.k)("act6/act6_domain_filing_vs_grant.json"),{subfieldPivot:Y,subfieldNames:X}=(0,a.useMemo)(()=>{if(!i)return{subfieldPivot:[],subfieldNames:[]};let e=[...new Set(i.map(e=>e.subfield))];return{subfieldPivot:[...new Set(i.map(e=>e.year))].sort().map(e=>{let t={year:e};return i.filter(t=>t.year===e).forEach(e=>{t[e.subfield]=e.count}),t}),subfieldNames:e}},[i]),$=(0,a.useMemo)(()=>B?B.map(e=>({...e,label:(0,j.K)(e.organization)})):[],[B]),ee=(0,a.useMemo)(()=>A?A.map(e=>({...e,label:"".concat(e.first_name," ").concat(e.last_name).trim()})):[],[A]),et=(0,a.useMemo)(()=>{if(!I)return{};let e={};return[...new Set(I.map(e=>e.organization))].forEach(t=>{e[t]=(0,j.K)(t)}),e},[I]),ei=(0,a.useMemo)(()=>{if(!I)return[];let e=[...new Set(I.map(e=>e.year))].sort().filter(e=>e>=1990),t=[];return e.forEach(e=>{I.filter(t=>t.year===e&&t.count>0).sort((e,t)=>t.count-e.count).forEach((i,n)=>{if(n<15){var a;t.push({organization:null!==(a=et[i.organization])&&void 0!==a?a:i.organization,year:e,rank:n+1})}})}),t},[I,et]),en=(0,a.useMemo)(()=>{if(!z)return[];let e={};return z.forEach(t=>{e[t.country]=(e[t.country]||0)+t.domain_patents}),Object.entries(e).map(e=>{let[t,i]=e;return{country:t,domain_patents:i}}).sort((e,t)=>t.domain_patents-e.domain_patents).slice(0,30)},[z]),ea=(0,a.useMemo)(()=>z?z.filter(e=>"US"===e.country&&e.state).sort((e,t)=>t.domain_patents-e.domain_patents).slice(0,30).map(e=>({state:e.state,domain_patents:e.domain_patents})):[],[z]),eo=(0,a.useMemo)(()=>L?[...new Set(L.map(e=>e.organization))].map(e=>({organization:e,subfields:L.filter(t=>t.organization===e).sort((e,t)=>t.patent_count-e.patent_count)})).sort((e,t)=>{let i=e.subfields.reduce((e,t)=>e+t.patent_count,0);return t.subfields.reduce((e,t)=>e+t.patent_count,0)-i}):[],[L]),{diffusionPivot:es,diffusionSections:er}=(0,a.useMemo)(()=>{if(!U)return{diffusionPivot:[],diffusionSections:[]};let e=[...new Set(U.map(e=>e.section))].sort();return{diffusionPivot:[...new Set(U.map(e=>e.year))].sort((e,t)=>e-t).map(e=>{let t={year:e};return U.filter(t=>t.year===e).forEach(e=>{t[e.section]=e.pct_of_domain}),t}),diffusionSections:e}},[U]),ec=(0,a.useMemo)(()=>H?[...new Set(H.map(e=>e.year))].sort().map(e=>{let t={year:e};return H.filter(t=>t.year===e).forEach(e=>{t[e.category]=e.avg_team_size}),t}):[],[H]),{assigneeTypePivot:el,assigneeTypeNames:eh}=(0,a.useMemo)(()=>{if(!G)return{assigneeTypePivot:[],assigneeTypeNames:[]};let e=[...new Set(G.map(e=>e.assignee_category))];return{assigneeTypePivot:[...new Set(G.map(e=>e.year))].sort().map(e=>{let t={year:e};return G.filter(t=>t.year===e).forEach(e=>{t[e.assignee_category]=e.count}),t}),assigneeTypeNames:e}},[G]),ed=(0,a.useMemo)(()=>Z?Z.map(e=>({year:e.year,Entrant:e.entrant_count,Incumbent:e.incumbent_count})):[],[Z]),eg=(0,a.useMemo)(()=>{if(!I||!e)return[];let t=Object.fromEntries(e.map(e=>[e.year,e.domain_patents]));return[...new Set(I.map(e=>e.year))].sort().map(e=>{let i=I.filter(t=>t.year===e).sort((e,t)=>t.count-e.count).slice(0,4).reduce((e,t)=>e+t.count,0),n=t[e]||1;return{year:e,cr4:+(i/n*100).toFixed(1)}}).filter(e=>e.cr4>0)},[I,e]),eu=(0,a.useMemo)(()=>i?[...new Set(i.map(e=>e.year))].sort().map(e=>{let t=i.filter(t=>t.year===e&&t.count>0),n=t.reduce((e,t)=>e+t.count,0),a=t.length;return 0===n||a<=1?{year:e,entropy:0}:{year:e,entropy:+(-t.reduce((e,t)=>{let i=t.count/n;return e+i*Math.log(i)},0)/Math.log(a)).toFixed(3)}}).filter(e=>e.entropy>0):[],[i]),em=(0,a.useMemo)(()=>{if(!B)return[];let e={};return B.forEach(t=>{let i=10*Math.floor(t.first_year/10),n="".concat(i,"s");n in e||(e[n]={count:0,totalPat:0,totalSpan:0}),e[n].count++,e[n].totalPat+=t.domain_patents,e[n].totalSpan+=Math.max(1,t.last_year-t.first_year+1)}),Object.entries(e).sort((e,t)=>{let[i]=e,[n]=t;return i.localeCompare(n)}).filter(e=>{let[,t]=e;return t.count>=3}).map(e=>{let[t,i]=e;return{decade:t,velocity:+(i.totalPat/i.totalSpan).toFixed(1),count:i.count}})},[B]),ep=(0,a.useMemo)(()=>{if(!W)return[];let e=W.filter(e=>"Biotech"===e.domain&&"filing_year"===e.series),t=W.filter(e=>"Biotech"===e.domain&&"grant_year"===e.series),i=Object.fromEntries(e.map(e=>[e.year,e.count])),n=Object.fromEntries(t.map(e=>[e.year,e.count]));return[...new Set([...e.map(e=>e.year),...t.map(e=>e.year)])].sort().map(e=>{var t,a;return{year:e,filings:null!==(t=i[e])&&void 0!==t?t:0,grants:null!==(a=n[e])&&void 0!==a?a:0}})},[W]);return(0,n.jsxs)("div",{children:[(0,n.jsx)(s.K,{number:27,title:"Biotechnology & Gene Editing",subtitle:"Engineering life at the molecular level"}),(0,n.jsx)(w.x,{slug:"biotechnology"}),(0,n.jsxs)(y.u,{children:[(0,n.jsx)("li",{children:"Biotechnology patenting has grown substantially since the 1980s, following the Bayh-Dole Act (1980), which permitted universities to patent federally funded inventions."}),(0,n.jsx)("li",{children:"The completion of the Human Genome Project in 2003 and the publication of CRISPR-Cas9 gene editing in 2012 represent inflection points that reshaped the composition of biotech patents, shifting activity toward genomic technologies and precision gene editing."}),(0,n.jsx)("li",{children:"Unlike AI patenting, which is dominated by technology firms, biotech patents are concentrated among research universities (University of California, Harvard, Stanford), agricultural biotech firms (Monsanto, Pioneer Hi-Bred, DuPont), and enzyme companies (Novozymes), reflecting the distinct institutional structure of life sciences innovation."}),(0,n.jsx)("li",{children:"The development and patenting of mRNA vaccine technology during the COVID-19 pandemic occurred at an accelerated pace relative to typical biotech development timelines."})]}),(0,n.jsxs)("aside",{className:"my-8 rounded-lg border bg-muted/30 p-5",children:[(0,n.jsx)("h2",{className:"mb-2 text-sm font-semibold uppercase tracking-wide text-muted-foreground",children:"Executive Summary"}),(0,n.jsx)("p",{className:"text-sm leading-relaxed",children:"Biotechnology patenting in the United States reflects a half-century transformation in how society harnesses molecular biology for commercial and therapeutic purposes. The Bayh-Dole Act of 1980 coincided with a substantial expansion of university-originated patents, while the completion of the Human Genome Project in 2003 and the discovery of CRISPR-Cas9 gene editing in 2012 coincided with successive waves of inventive activity. The institutional landscape of biotech patenting differs markedly from domains such as artificial intelligence: research universities, agricultural biotech firms, enzyme companies, and life sciences tools makers play prominent roles, and the ethical and regulatory dimensions of gene editing technology create unique constraints on how patents translate into products. The COVID-19 pandemic further demonstrated the strategic importance of biotech patent portfolios, as mRNA vaccine technology moved from laboratory concept to global deployment in under a year. This chapter traces the growth, composition, and organizational structure of biotechnology patenting across the full span of the modern patent system."})]}),(0,n.jsxs)(r.n,{children:[(0,n.jsxs)("p",{children:["Having examined ",(0,n.jsx)(k.default,{href:"/chapters/autonomous-vehicles/",className:"underline decoration-muted-foreground/50 hover:decoration-foreground transition-colors",children:"autonomous vehicles"})," and the convergence of AI, sensing, and control systems in transportation, this chapter turns to biotechnology, a domain defined by fundamentally different innovation dynamics rooted in molecular biology and regulatory constraints."]}),(0,n.jsx)("p",{children:"Biotechnology occupies a distinctive position within the patent system. Unlike most technology domains where the path from invention to commercialization is relatively direct, biotech patents frequently emerge from basic scientific research conducted at universities and government laboratories, traverse lengthy regulatory approval processes, and raise profound ethical questions about the boundaries of patentable subject matter. This chapter examines the trajectory of biotechnology and gene editing patents -- from the recombinant DNA revolution of the 1970s through the genomic era and the current frontier of precision gene editing."})]}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"Biotechnology patent activity serves as a barometer of the life sciences innovation ecosystem. The field has been shaped by a series of landmark scientific breakthroughs -- recombinant DNA technology, polymerase chain reaction, the Human Genome Project, and CRISPR-Cas9 -- each of which generated distinctive waves of patenting activity. The interplay between academic discovery, commercial development, and regulatory oversight makes biotech patenting uniquely complex among technology domains."})}),(0,n.jsx)(m.d,{label:"Growth Trajectory"}),(0,n.jsx)(l.B,{id:"fig-biotech-annual-count",subtitle:"Annual count of utility patents classified under biotechnology-related CPC codes, tracking the growth trajectory of biotech patenting.",title:"Biotechnology Patent Filings Have Grown Substantially Since the 1980s, With Notable Fluctuations",caption:"Annual count of utility patents classified under biotechnology-related CPC codes, 1976-2025. The growth trajectory reflects successive waves following the Bayh-Dole Act (1980), the Human Genome Project completion (2003), and the CRISPR-Cas9 publication (2012). Grant year shown. Application dates are typically 2–3 years earlier.",insight:"The sustained growth of biotech patents reflects the expanding commercial potential of molecular biology, with each major scientific breakthrough coinciding with a new wave of inventive activity.",loading:t,children:(0,n.jsx)(h.J,{data:null!=e?e:[],xKey:"year",lines:[{key:"domain_patents",name:"Biotech Patents",color:C.ZE[0]}],yLabel:"Number of Patents",referenceLines:T.VT})}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"Biotechnology patent filings have exhibited substantial growth since the early 1980s, following the Bayh-Dole Act which enabled universities to patent inventions arising from federally funded research. This legislative change was consequential for the life sciences, creating a direct pathway from academic laboratories to commercial development. The completion of the Human Genome Project in 2003 accelerated genomic patenting, while the publication of CRISPR-Cas9 gene editing technology in 2012 opened a new frontier of precision genetic engineering."})}),(0,n.jsx)(l.B,{id:"fig-biotech-entrant-incumbent",title:"Biotechnology Patenting Shows Persistent Incumbent Strength With Steady Entrant Inflows",subtitle:"Annual patent counts from entrant and incumbent assignees in the biotechnology domain.",caption:"Entrants are organizations filing their first biotech patent in a given year; incumbents are those with prior filings.",loading:F,children:(0,n.jsx)(d.Z,{data:ed,xKey:"year",areas:[{key:"Entrant",name:"Entrant",color:C.ZE[1]},{key:"Incumbent",name:"Incumbent",color:C.ZE[0]}],stacked:!0,yLabel:"Number of Patents"})}),(0,n.jsx)(l.B,{id:"fig-biotech-share",subtitle:"Biotech patents as a percentage of all utility patents, showing the evolving weight of life sciences in the innovation system.",title:"Biotechnology's Share of Total Patents Reflects the Centrality of Life Sciences Innovation",caption:"Percentage of all utility patents classified under biotechnology-related CPC codes. Biotech's share has fluctuated over time, reflecting how molecular biology has become a stable but significant component of the patent system.",insight:"The growing share of biotech patents among all patents demonstrates that life sciences innovation is not merely tracking overall patent expansion but represents a genuine structural shift in the composition of inventive activity reflected in the USPTO record.",loading:t,children:(0,n.jsx)(h.J,{data:null!=e?e:[],xKey:"year",lines:[{key:"domain_pct",name:"Biotech Share (%)",color:C.ZE[3]}],yLabel:"Share (%)",yFormatter:e=>"".concat(e.toFixed(1),"%"),referenceLines:T.VT})}),(0,n.jsx)(m.d,{label:"Biotech Subfields"}),(0,n.jsx)(l.B,{id:"fig-biotech-subfields",subtitle:"Patent counts by biotechnology subfield (gene editing, recombinant DNA, enzyme engineering, and other subfields) over time, based on CPC classifications.",title:"Recombinant DNA and Expression Vectors Are Among the Largest Growing Biotech Subfields",caption:"Patent counts by biotechnology subfield over time, based on CPC classifications. The data reveal substantial growth in recombinant DNA and expression vectors since 2012, alongside the expansion of gene editing and nucleic acid detection methods.",insight:"The subfield composition of biotech patents has shifted substantially since 2012, with recombinant DNA technology continuing to grow substantially, while gene editing and expression vector technologies have also expanded considerably.",loading:S,height:650,children:(0,n.jsx)(d.Z,{data:Y,xKey:"year",areas:X.map(e=>{var t;return{key:e,name:e,color:null!==(t=C.YK[e])&&void 0!==t?t:"#999999"}}),stacked:!0,yLabel:"Number of Patents",referenceLines:T.VT})}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"The composition of biotechnology patents has evolved substantially over the past five decades. Early biotech patenting was concentrated in enzyme engineering. Since 2012, gene editing and modification patents have expanded substantially, associated with the development of CRISPR-Cas9 technology, which enabled more precise genomic alterations. Enzyme engineering and nucleic acid detection have also experienced considerable growth, reflecting advances in directed evolution (recognized by the 2018 Nobel Prize in Chemistry) and the proliferation of PCR-based and advanced sequencing diagnostic platforms, particularly during the COVID-19 pandemic."})}),(0,n.jsx)(m.d,{label:"Leading Organizations"}),(0,n.jsx)(l.B,{id:"fig-biotech-top-assignees",subtitle:"Organizations ranked by total biotechnology patent count, showing the institutional landscape of life sciences innovation.",title:"Research Universities and Agricultural Biotech Firms Dominate Biotechnology Patenting",caption:"Organizations ranked by total biotechnology-related patents, 1976-2025. The data reveal a distinctive institutional mix: research universities (University of California, Harvard, Stanford), agricultural biotech firms (Monsanto, Pioneer Hi-Bred, DuPont), and enzyme companies (Novozymes) dominate the rankings, reflecting the diverse origins of biotech innovation.",insight:"The organizational landscape of biotech patenting differs markedly from AI, where large technology firms dominate. In biotechnology, research universities, agricultural biotech firms, enzyme companies, and life sciences tools makers are the major patent holders, reflecting the field's diverse institutional roots.",loading:N,height:1400,children:(0,n.jsx)(g.o,{data:$,xKey:"label",bars:[{key:"domain_patents",name:"Biotech Patents",color:C.ZE[0]}],layout:"vertical"})}),(0,n.jsx)(x.T,{title:"View top biotech patent holders as a data table",headers:["Organization","Biotech Patents"],rows:(null!=B?B:[]).slice(0,15).map(e=>[(0,j.K)(e.organization),e.domain_patents]),caption:"Top 15 organizations by biotechnology patent count, 1976-2025. Source: PatentsView."}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"The leading biotechnology patent holders reflect the distinctive institutional structure of life sciences innovation. Unlike artificial intelligence, where technology corporations overwhelmingly dominate, biotech patenting features a diverse organizational landscape. Agricultural biotech firms such as Monsanto, Pioneer Hi-Bred, and DuPont are among the top patent holders, alongside enzyme companies like Novozymes. Research universities -- empowered by the Bayh-Dole Act -- hold prominent positions, with the University of California ranking first overall, and Harvard and Stanford also in the top ten. This mix of agricultural biotech, life sciences tools companies, and academic institutions is a defining feature of the biotech innovation ecosystem, with technology transfer offices serving as critical intermediaries between academic discovery and commercial application."})}),ei.length>0&&(0,n.jsx)(l.B,{id:"fig-biotech-org-rankings",subtitle:"Annual ranking of the top 15 organizations by biotechnology patent grants, with darker cells indicating higher rank.",title:"Organizational Leadership in Biotech Patenting Has Shifted as Gene Editing and mRNA Technologies Reshaped Competitive Dynamics",caption:"Annual ranking of the top 15 organizations by biotechnology patent grants, 1990-2025. Darker cells indicate higher rank (more patents). The data reveal how successive technological waves -- genomics, gene editing, and mRNA -- have altered the competitive landscape of biotech patenting.",insight:"The organizational rankings reveal dynamic competition in biotech patenting, with pharmaceutical incumbents facing challenges from specialized biotechnology firms and research-intensive universities as new technologies reshape the field.",loading:M,height:600,flexHeight:!0,wide:!0,children:(0,n.jsx)(u.G,{data:ei,nameKey:"organization",yearKey:"year",rankKey:"rank",maxRank:15,yearInterval:2})}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"The ranking data illustrate how successive technological breakthroughs have reshaped organizational leadership in biotech patenting. The completion of the Human Genome Project was followed by a wave of genomic patenting that benefited firms positioned in sequencing and diagnostics. The CRISPR revolution after 2012 created new competitive dynamics, with specialized gene editing companies and academic institutions claiming significant patent positions. The COVID-19 pandemic further disrupted rankings as mRNA platform companies rapidly expanded their patent portfolios. These shifts underscore how, in biotechnology, scientific breakthroughs can rapidly alter the organizational hierarchy of innovation."})}),(0,n.jsx)(m.d,{label:"Top Inventors"}),(0,n.jsx)(l.B,{id:"fig-biotech-top-inventors",subtitle:"Primary inventors ranked by total biotechnology patent count, illustrating the distribution of individual inventive output in the life sciences.",title:"The Most Prolific Biotech Inventors Reflect the Field's Deep Connection to Academic Research and Pharmaceutical R&D",caption:"Primary inventors ranked by total biotechnology-related patents, 1976-2025. The distribution reveals that prolific biotech inventors are frequently affiliated with universities and pharmaceutical firms, reflecting the academic origins of many biotech breakthroughs.",insight:"The concentration of biotech patenting among prolific inventors affiliated with universities and pharmaceutical companies highlights the field's dependence on deep scientific expertise and long-term research programs.",loading:_,height:1400,children:(0,n.jsx)(g.o,{data:ee,xKey:"label",bars:[{key:"domain_patents",name:"Biotech Patents",color:C.ZE[4]}],layout:"vertical"})}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"The most prolific biotechnology inventors are characteristically affiliated with research universities and pharmaceutical companies that maintain long-term programs in genetic engineering, molecular biology, and drug development. Unlike AI, where the most productive inventors tend to cluster in corporate research laboratories of technology firms, biotech invention exhibits a stronger connection to academic science. Many of the leading biotech inventors hold joint appointments as university faculty and industry consultants, embodying the dual institutional structure that defines life sciences innovation."})}),(0,n.jsx)(m.d,{label:"Geographic Distribution"}),(0,n.jsx)(l.B,{id:"fig-biotech-by-country",subtitle:"Countries ranked by total biotechnology patents based on primary inventor location, showing the geographic distribution of biotech innovation.",title:"The United States Leads in Biotech Patenting, With Significant Contributions From Japan, Germany, and Emerging Asian Economies",caption:"Countries ranked by total biotechnology-related patents based on primary inventor location. The United States maintains a substantial lead, reflecting its extensive network of research universities, NIH-funded research, and pharmaceutical industry concentration.",insight:"The geographic distribution of biotech patents reflects the importance of national research funding infrastructure, regulatory frameworks, and the concentration of pharmaceutical and life sciences firms.",loading:E,height:900,children:(0,n.jsx)(g.o,{data:en,xKey:"country",bars:[{key:"domain_patents",name:"Biotech Patents",color:C.ZE[2]}],layout:"vertical"})}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"The geographic distribution of biotechnology patents reveals the dominant role of the United States, which benefits from the world's largest biomedical research funding apparatus through the National Institutes of Health, a dense network of research universities, and the concentration of major life sciences firms. Japan and Germany maintain strong positions reflecting their historical strengths in chemical and pharmaceutical engineering. The United Kingdom and France also rank prominently, ahead of China and South Korea, reflecting Europe's deep life sciences research tradition. The growing presence of China and South Korea in biotech patenting signals the expansion of life sciences capabilities in East Asia, reflecting substantial government investment in genomics and biomanufacturing."})}),(0,n.jsx)(l.B,{id:"fig-biotech-by-state",subtitle:"US states ranked by total biotechnology patents based on primary inventor location, highlighting geographic clustering within the United States.",title:"Biotech Patenting Clusters in States With Major Research Universities and Pharmaceutical Industry Presence",caption:"US states ranked by total biotechnology-related patents based on primary inventor location. The data reflect the co-location of research universities, NIH-funded medical centers, pharmaceutical companies, and venture capital that characterizes leading biotech hubs.",insight:"The state-level distribution of biotech patents reveals distinct clusters reflecting the co-location of research universities, teaching hospitals, pharmaceutical firms, and venture capital -- the key ingredients of the biotech innovation ecosystem.",loading:E,height:900,children:(0,n.jsx)(g.o,{data:ea,xKey:"state",bars:[{key:"domain_patents",name:"Biotech Patents",color:C.ZE[3]}],layout:"vertical"})}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"Within the United States, biotechnology patenting clusters in states that combine leading research universities, NIH-funded medical centers, life sciences industry headquarters, and venture capital availability. California and Massachusetts are particularly prominent, reflecting the Bay Area biotech corridor and the Boston-Cambridge life sciences cluster. Iowa ranks sixth nationally, anchored by Pioneer Hi-Bred's agricultural biotechnology headquarters, illustrating the significant role of crop science in biotech patenting. New Jersey benefits from its historical concentration of pharmaceutical and life sciences companies, while states such as Maryland and North Carolina have developed growing biotech ecosystems anchored by research triangle institutions and federal research facilities."})}),(0,n.jsx)(m.d,{label:"Quality Indicators"}),(0,n.jsx)(l.B,{id:"fig-biotech-quality",subtitle:"Average claims, backward citations, and technology scope (CPC subclasses) for biotechnology patents by year, measuring quality trends.",title:"Biotech Patent Quality Indicators Reveal Growing Complexity and Interdisciplinarity Over Time",caption:"Average claims, backward citations, and technology scope for biotechnology-related patents by year. The trends suggest that biotech patents have become more complex and interconnected, consistent with the expanding intersection of molecular biology with informatics, engineering, and clinical science.",insight:"Rising backward citations and technology scope suggest that biotech patents are becoming increasingly interconnected and interdisciplinary, reflecting the convergence of molecular biology with computational methods, materials science, and clinical applications.",loading:D,children:(0,n.jsx)(h.J,{data:null!=R?R:[],xKey:"year",lines:[{key:"avg_claims",name:"Average Claims",color:C.ZE[0]},{key:"avg_backward_cites",name:"Average Backward Citations",color:C.ZE[2]},{key:"avg_scope",name:"Average Scope (CPC Subclasses)",color:C.ZE[4]}],yLabel:"Average per Patent",yFormatter:e=>e.toFixed(1),referenceLines:T.VT})}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"Biotechnology patents exhibit distinctive quality characteristics. The growing number of backward citations reflects the increasingly interconnected nature of life sciences research, where inventions build upon extensive prior art spanning molecular biology, biochemistry, pharmacology, and clinical medicine. The expanding technology scope indicates that biotech inventions increasingly span multiple CPC subclasses, consistent with the convergence of biological engineering with computational methods, materials science, and medical device technology. The trend in claim counts reflects evolving patent drafting strategies in the life sciences, where applicants must navigate complex patentability requirements for biological subject matter."})}),(0,n.jsx)(l.B,{id:"fig-biotech-quality-bifurcation",title:"Biotechnology Maintained Above-Average Top-Decile Citation Share Throughout Its History",subtitle:"Share of biotech patents in the top decile of forward citations, by grant year.",caption:"Top-decile citation share measures the proportion of domain patents that rank in the top 10% of all patents by forward citations received.",loading:J,children:(0,n.jsx)(h.J,{data:null!=V?V:[],xKey:"year",lines:[{key:"top_decile_share",name:"Top-Decile Share (%)",color:C.ZE[2]}],yLabel:"Top-Decile Share (%)"})}),(0,n.jsx)(m.d,{label:"Biotech Patenting Strategies"}),(0,n.jsx)(r.n,{children:(0,n.jsx)("p",{children:"The leading biotechnology patent holders pursue distinct strategic approaches. Some organizations concentrate heavily on gene editing and modification technologies, while others maintain diversified portfolios spanning recombinant DNA, enzyme engineering, and nucleic acid detection. A comparison of subfield portfolios across major holders reveals the strategic choices that define each organization's approach to biotech innovation and identifies subfields where competitive intensity is highest."})}),eo.length>0&&(0,n.jsx)("div",{className:"max-w-4xl mx-auto my-8 overflow-x-auto",children:(0,n.jsxs)("table",{className:"w-full text-xs",children:[(0,n.jsx)("thead",{children:(0,n.jsxs)("tr",{className:"border-b border-border",children:[(0,n.jsx)("th",{className:"text-left py-2 px-2 font-medium text-muted-foreground",children:"Organization"}),(0,n.jsx)("th",{className:"text-left py-2 px-2 font-medium text-muted-foreground",children:"Top Sub-Areas"}),(0,n.jsx)("th",{className:"text-right py-2 px-2 font-medium text-muted-foreground",children:"Total Biotech Patents"})]})}),(0,n.jsx)("tbody",{children:eo.slice(0,15).map((e,t)=>(0,n.jsxs)("tr",{className:"border-b border-border/50",children:[(0,n.jsx)("td",{className:"py-2 px-2 font-medium text-sm",children:(0,j.K)(e.organization)}),(0,n.jsx)("td",{className:"py-2 px-2",children:e.subfields.slice(0,3).map((e,t)=>(0,n.jsxs)("span",{className:"inline-block mr-2 px-1.5 py-0.5 rounded bg-muted text-muted-foreground",children:[e.subfield,": ",e.patent_count.toLocaleString("en-US")]},t))}),(0,n.jsx)("td",{className:"text-right py-2 px-2 font-mono font-semibold",children:e.subfields.reduce((e,t)=>e+t.patent_count,0).toLocaleString("en-US")})]},t))})]})}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"The strategic portfolios of leading biotech patent holders reveal distinctive organizational approaches. Agricultural biotech firms concentrate heavily on genetic engineering categories, reflecting their focus on crop trait engineering. Research universities often hold stronger positions in gene editing and fundamental genetic engineering methods, reflecting their role as originators of basic scientific breakthroughs. Specialized biotechnology firms frequently focus on narrow but high-value niches such as enzyme engineering or nucleic acid detection platforms. The diversity of strategic approaches across organizations underscores the breadth of the biotechnology field and the multiple pathways through which inventive effort can create commercial value."})}),(0,n.jsx)(m.d,{label:"Biotech as a Platform Technology"}),(0,n.jsx)(r.n,{children:(0,n.jsx)("p",{children:"A defining characteristic of platform technologies is their diffusion into multiple sectors of the economy. By tracking how frequently biotechnology-classified patents also carry CPC codes from non-biotech technology areas, it is possible to measure the spread of biotech methods into healthcare delivery, agriculture, industrial chemistry, and other domains. The breadth of this diffusion provides evidence for biotechnology's role as a foundational technology with applications far beyond its immediate field."})}),(0,n.jsx)(l.B,{id:"fig-biotech-diffusion",subtitle:"Percentage of biotech patents co-classified with non-biotech CPC sections, measuring biotechnology's diffusion into healthcare, agriculture, and industry.",title:"Biotechnology Patents Show Increasing Co-Classification With Healthcare, Physics, and Agricultural CPC Codes",caption:"Percentage of biotechnology patents that also carry CPC codes from each non-biotech CPC section. Rising lines indicate biotech methods diffusing into that sector. The most prominent pattern is the strong and growing co-occurrence with Human Necessities (Section A, encompassing healthcare and agriculture) and Physics (Section G, encompassing measurement and testing technologies).",insight:"The co-classification of biotech patents with healthcare (Section A) and physics (Section G) CPC codes reflects the fundamental role of molecular biology in drug development, agriculture, diagnostics, and measurement technologies. The growing co-occurrence with other sections suggests expanding applications of biotech methods across the economy.",loading:q,children:es.length>0&&(0,n.jsx)(h.J,{data:es,xKey:"year",lines:er.map(e=>{var t;return{key:e,name:"".concat(e,": ").concat(null!==(t=P.Ph[e])&&void 0!==t?t:e),color:C.Dn[e]}}),yLabel:"% of Biotech Patents",yFormatter:e=>"".concat(e.toFixed(1),"%"),referenceLines:T.VT})}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"Biotechnology exhibits the characteristics of a platform technology with broad applicability across the economy. The strong co-classification with Human Necessities (Section A) reflects biotech's deep connections to healthcare, pharmaceuticals, and agriculture -- the sectors where genetic engineering has had its most significant impact. The substantial co-occurrence with Physics (Section G, encompassing measurement and testing technologies) reflects the importance of analytical and diagnostic instrumentation in the field, while growing connections to other sections suggest that biotech methods are increasingly being applied to industrial processes, materials science, and environmental remediation. This cross-domain diffusion pattern supports the characterization of biotechnology as a general-purpose technology whose influence extends well beyond the life sciences."})}),(0,n.jsx)(m.d,{label:"The Collaborative Structure of Biotech Innovation"}),(0,n.jsx)(r.n,{children:(0,n.jsx)("p",{children:"Biotechnology patents increasingly involve larger inventor teams, reflecting the multidisciplinary nature of modern life sciences research. Comparing team sizes between biotech and non-biotech patents reveals how the collaborative demands of genetic engineering, clinical trials, and regulatory compliance shape the structure of inventive activity in the life sciences."})}),(0,n.jsx)(l.B,{id:"fig-biotech-team-comparison",subtitle:"Average inventors per patent for biotech versus non-biotech utility patents by year, showing the widening collaboration gap.",title:"Biotech Patents Consistently Involve Larger Teams Than Non-Biotech Patents, Reflecting the Multidisciplinary Demands of Life Sciences",caption:"Average number of inventors per patent for biotechnology-related versus non-biotech utility patents, 1976-2025. The data indicate that biotech patents have consistently involved larger teams, and the gap has widened as the complexity of genetic engineering, genomics, and clinical development has increased.",insight:"Biotech patents consistently involve larger teams than non-biotech patents, and the gap has widened over time. This pattern reflects the inherent multidisciplinarity of life sciences innovation, which requires collaboration across molecular biology, chemistry, clinical medicine, and increasingly computational science.",loading:K,children:(0,n.jsx)(h.J,{data:ec,xKey:"year",lines:[{key:"Biotech",name:"Biotech Patents",color:C.ZE[0]},{key:"Non-Biotech",name:"Non-Biotech Patents",color:C.ZE[3]}],yLabel:"Average Team Size",yFormatter:e=>e.toFixed(1)})}),(0,n.jsx)(l.B,{id:"fig-biotech-assignee-type",subtitle:"Distribution of biotech patents by assignee type (corporate, university, government, individual) over time, revealing the distinctive institutional mix.",title:"Corporate Assignees Dominate Aggregate Biotech Patent Counts, Though Individual Universities Rank Highly",caption:'Distribution of biotechnology patent assignees by type (corporate, university, government, individual) over time. Corporate assignees account for 96-98% of biotech patents in the aggregate categorization. While individual universities such as the University of California (#1 overall), Harvard (#8), and Stanford (#10) rank among the top assignees, the aggregate "University/Other" category remains small, suggesting many university-originated patents may be assigned to corporate licensees.',insight:"The assignee type distribution reveals an apparent paradox: while individual universities rank among the top biotech patent holders, the aggregate University/Other category accounts for less than 1% of patents. This disconnect likely reflects the practice of assigning university-originated inventions to corporate licensees and spin-off companies.",loading:O,height:500,children:(0,n.jsx)(d.Z,{data:el,xKey:"year",areas:eh.map((e,t)=>({key:e,name:e,color:C.ZE[t%C.ZE.length]})),stacked:!0,yLabel:"Number of Patents"})}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"The distribution of biotechnology patents by assignee type reveals an instructive disconnect. Corporate assignees account for 96-98% of biotech patents in the aggregate data, yet individual universities rank among the very top assignees -- the University of California holds the most biotech patents of any organization, and Harvard and Stanford both appear in the top ten. This apparent paradox likely reflects the common practice whereby university-originated inventions are assigned to corporate licensees, spin-off companies, or joint ventures, causing them to appear as corporate patents in aggregate categorizations. The Bayh-Dole Act's impact on academic patenting may thus be understated by aggregate assignee type data, as many commercially significant biotech inventions originate in university laboratories but are ultimately held by corporate entities."})}),(0,n.jsx)(m.d,{label:"Ethical and Regulatory Considerations"}),(0,n.jsxs)(r.n,{children:[(0,n.jsx)("p",{children:"Biotechnology and gene editing patents occupy a unique position at the intersection of innovation policy, bioethics, and public health regulation. The Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics (2013) established that naturally occurring DNA sequences cannot be patented, while synthetic cDNA remains patentable -- a distinction that continues to shape patent strategy in genomics. The ongoing CRISPR patent dispute between the Broad Institute and the University of California illustrates how foundational biotech patents can become the subject of protracted legal battles with billions of dollars in commercial value at stake."}),(0,n.jsx)("p",{children:"Gene editing technologies raise particularly acute ethical questions. The ability to modify human germline cells -- changes that would be inherited by future generations -- has prompted international calls for moratoriums and regulatory frameworks that have no parallel in other technology domains. These ethical and regulatory dimensions create unique constraints on how biotech patents translate into products and therapies, distinguishing the field from domains such as artificial intelligence or semiconductors where the path from patent to market is less encumbered by ethical oversight."})]}),(0,n.jsx)(p.c,{children:(0,n.jsx)("p",{children:"The ethical and regulatory landscape surrounding biotechnology patents creates both constraints and incentives that shape inventive activity in distinctive ways. Patent exclusivity provides the economic incentive necessary to justify the substantial investment required for drug development and clinical trials -- a process that typically costs over a billion dollars and spans more than a decade. At the same time, the patentability of biological materials remains subject to evolving legal standards and ethical considerations that have no direct analogue in other technology domains. The tension between incentivizing innovation and ensuring equitable access to life-saving technologies -- exemplified by debates over mRNA vaccine patents during the COVID-19 pandemic -- remains one of the most consequential policy questions in the modern patent system."})}),(0,n.jsx)(m.d,{label:"Analytical Deep Dives"}),(0,n.jsxs)("p",{className:"text-sm text-muted-foreground mt-4",children:["For metric definitions and cross-domain comparisons, see the ",(0,n.jsx)(k.default,{href:"/chapters/deep-dive-overview/",className:"underline decoration-muted-foreground/50 hover:decoration-foreground transition-colors",children:"ACT 6 Overview"}),"."]}),(0,n.jsx)(l.B,{id:"fig-biotech-cr4",subtitle:"Share of annual domain patents held by the four largest organizations, measuring organizational concentration in biotechnology patenting.",title:"Top-4 Concentration in Biotechnology Patents Peaked at 13.5% in 2007 Before Declining to 4.6% by 2025",caption:"CR4 computed as the sum of the top 4 organizations' annual patent counts divided by total domain patents. Biotechnology exhibits the lowest peak concentration among ACT 6 domains, reflecting the highly distributed nature of life sciences research across universities, startups, and pharmaceutical firms.",insight:"The low and declining concentration is consistent with the Bayh-Dole Act's legacy of distributed university patenting and the biotech sector's reliance on specialized startups rather than large vertically integrated firms.",loading:M||t,children:(0,n.jsx)(h.J,{data:eg,xKey:"year",lines:[{key:"cr4",name:"Top-4 Share (%)",color:C.ZE[0]}],yLabel:"CR4 (%)"})}),(0,n.jsx)(l.B,{id:"fig-biotech-entropy",subtitle:"Normalized Shannon entropy of subfield patent distributions, measuring how evenly inventive activity is spread across biotechnology subfields.",title:"Biotechnology Subfield Diversity Tripled From 0.32 in 1976 to 0.94 by 2025, Reflecting the Field's Maturation",caption:"Normalized Shannon entropy increased from 0.32 (dominated by recombinant DNA) to 0.94 (broadly distributed across gene editing, expression vectors, cell engineering, and diagnostics). This trajectory reflects the successive waves of innovation from recombinant DNA to PCR to CRISPR.",insight:"The biotechnology diversification trajectory parallels AI's but is shaped by different mechanisms: successive breakthrough technologies (PCR, monoclonal antibodies, CRISPR) each opened new subfields, progressively balancing the distribution of inventive activity.",loading:S,children:(0,n.jsx)(h.J,{data:eu,xKey:"year",lines:[{key:"entropy",name:"Diversity Index",color:C.ZE[2]}],yLabel:"Normalized Entropy",yDomain:[0,1]})}),(0,n.jsx)(l.B,{id:"fig-biotech-velocity",subtitle:"Mean patents per active year for top organizations grouped by the decade in which they first filed a biotechnology patent.",title:"Later Biotech Entrants Patent at Modestly Higher Velocity: 2000s Cohort Averages 26.9 Patents per Year Versus 19.2 for 1970s Entrants",caption:"Mean patents per active year for top biotech organizations grouped by entry decade. The 1.4x increase is the smallest among mature ACT 6 domains, suggesting that biotechnology patenting has not become substantially easier over time, consistent with the domain's high regulatory and scientific barriers.",insight:"The modest velocity increase contrasts with AI's 2.0x and green innovation's 5.5x ratios, reflecting the persistent barriers to biotech patenting imposed by regulatory requirements, clinical validation timelines, and the fundamental complexity of biological systems.",loading:N,children:(0,n.jsx)(g.o,{data:em,xKey:"decade",bars:[{key:"velocity",name:"Patents per Year",color:C.ZE[1]}],yLabel:"Average Patents per Year"})}),(0,n.jsx)(l.B,{id:"fig-biotech-filing-vs-grant",title:"Biotech Filings Peaked at 4,763 in 2018 While Grants Reached 4,360 in 2020 — Reflecting Lengthy Examination Times",subtitle:"Annual patent filings versus grants for biotechnology, showing the filing-to-grant pipeline.",caption:"Biotechnology patents exhibit a moderate filing-to-grant lag. Filings peaked in 2018 and have since declined, while grants peaked in 2020. The relatively stable grant output despite declining filings reflects the deep pipeline of biotech applications undergoing examination.",loading:Q,children:(0,n.jsx)(h.J,{data:ep,xKey:"year",lines:[{key:"filings",name:"Filings",color:C.ZE[0]},{key:"grants",name:"Grants",color:C.ZE[3]}],yLabel:"Number of Patents"})}),(0,n.jsx)(b.n,{learned:["Biotechnology achieved the lowest top-four concentration (4.6% by 2025) among all advanced technology domains, reflecting exceptionally broad-based participation.","Subfield diversity tripled from 0.32 in 1976 to 0.94 by 2025, reflecting successive waves from recombinant DNA to CRISPR-Cas9."],falsifiable:"If CRISPR drove the latest diversity wave, then gene-editing subclass patents should show discontinuous growth after the 2012 Doudna-Charpentier publication.",nextAnalysis:{label:"Blockchain",description:"Distributed trust in the digital economy — the only technology domain to reverse course",href:"/chapters/blockchain"}}),(0,n.jsx)(c.V,{children:"Biotechnology patents are identified using specific CPC groups within genetic engineering and molecular biology: C12N15 (mutation or genetic engineering), C12N9 (enzymes and proenzymes), and C12Q1/68 (nucleic acid detection). These targeted codes capture core molecular biotechnology while excluding broader C12N and C12Q categories that include conventional microbiology. Subfield classifications distinguish gene editing and modification, expression vectors, recombinant DNA, enzyme engineering, nucleic acid detection, and other genetic engineering categories. A patent is classified as biotechnology-related if any of its CPC codes fall within these categories. Geographic attribution is based on the primary inventor's location. Strategy data show patent counts per biotech sub-area for the top assignees. Diffusion analysis measures co-occurrence of biotech CPC codes with non-biotech CPC sections. Source: PatentsView / USPTO."}),(0,n.jsx)(v.M,{currentChapter:27}),(0,n.jsx)(f.W,{currentChapter:27})]})}},9778:function(e,t,i){"use strict";i.d(t,{T:function(){return a}});var n=i(57437);function a(e){let{title:t,headers:i,rows:a,caption:o}=e;return 0===a.length?null:(0,n.jsxs)("details",{className:"my-6 max-w-3xl mx-auto rounded-lg border bg-card",children:[(0,n.jsx)("summary",{className:"cursor-pointer px-4 py-3 text-sm font-medium text-muted-foreground hover:text-foreground transition-colors",children:t}),(0,n.jsxs)("div",{className:"overflow-x-auto px-4 pb-4",children:[(0,n.jsxs)("table",{className:"w-full text-sm",children:[(0,n.jsx)("thead",{children:(0,n.jsxs)("tr",{className:"border-b border-border",children:[(0,n.jsx)("th",{className:"text-right py-2 pr-3 font-medium text-muted-foreground w-10",children:"#"}),i.map((e,t)=>(0,n.jsx)("th",{className:"py-2 px-3 font-medium text-muted-foreground ".concat(0===t?"text-left":"text-right"),children:e},t))]})}),(0,n.jsx)("tbody",{children:a.map((e,t)=>(0,n.jsxs)("tr",{className:"border-b border-border/50",children:[(0,n.jsx)("td",{className:"text-right py-1.5 pr-3 font-mono text-xs text-muted-foreground",children:t+1}),e.map((e,t)=>(0,n.jsx)("td",{className:"py-1.5 px-3 ".concat(0===t?"text-left font-medium":"text-right font-mono"),children:"number"==typeof e?e.toLocaleString("en-US"):e},t))]},t))})]}),o&&(0,n.jsx)("figcaption",{className:"mt-2 text-xs text-muted-foreground",children:o})]})]})}}},function(e){e.O(0,[2972,917,553,1530,5736,894,6498,3796,2598,2971,2117,1744],function(){return e(e.s=38140)}),_N_E=e.O()}]);